Intercept Pharma (ICPT) Posts Q1 Loss of $5.17/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharma (ICPT) PT Drops To $221 - BMO
May 6, 2016 6:35 AM EDTBMO Analyst, Ian Somaiya, cut his PT on Intercept Pharmaceuticals (NASDAQ: ICPT) on slower NASH trial enrollment. Price target to $221 from $239.
Enrollment is now expected to complete in 1H17, and the analyst believes timelines now point to an early 2020 launch rather than... More
